Abstract 1
The in vivo stability and biodegradability of nanocarriers crucially determine 2 therapeutic efficacy as well as safety when used for drug delivery. We here aim to 3 evaluate optimized in vitro techniques predictive for in-vivo nanocarrier behavior. 4
Polymeric biodegradable nanogels based on hydroxyethyl methacrylamide-5 oligoglycolates-derivatized poly(hydroxyethyl methacrylamide-co-N-(2-6 azidoethyl)methacrylamide) (p(HEMAm-co-AzEMAm)-Gly-HEMAm) and with 7 various degrees of PEGylation and crosslinking densities were prepared. Three 8 techniques were chosen and refined for specific in vitro evaluation of the nanocarrier 9 performance: 1) fluorescence single particle tracking (fSPT) to study the stability of 10 nanogels in human plasma 2) tangential flow filtration (TFF) to study the degradation 11 and filtration of nanogel degradation products and 3) fluorescence fluctuation 12 spectroscopy (FFS) to evaluate and compare the degradation behavior of nanogels in 13 buffer and plasma. fSPT results demonstrated that nanogels with highest PEGylation 14 content showed the least aggregation. The TFF results revealed that nanogels with 15 higher crosslink density had slower degradation and removal by filtration. FFS results 16 indicated a similar degradation behavior in human plasma as compared to that in PBS. 17
In conclusion, three methods can be used to compare and select the optimal nanogel 18 composition, and hold potential to predict the in vivo performance of nanocarriers. 19 20 FIGURE FOR ToC_ABSTRACT 21 1. Introduction 1 Nanomedicines for intravenous administration have been extensively researched 2 and developed with expected advantages: improvement of solubility and stability of 3 drugs, generating more favorable pharmacokinetic and biodistribution behavior and 4 achieving controlled drug release. These unique properties result in significant 5 improvements in the efficacy and safety of the drugs [1] [2] [3] [4] . A key feature to realize these 6 advantages is a high stability and a controlled degradation behavior of the drug delivery 7 system in vivo. Various in vitro characterization methods have been established with 8 the aim to evaluate and optimize the stability and degradation behavior. However, those 9 strategies often appear of limited value in the prediction of in vivo performance [5] . For 10 instance, even though many colloidal drug carriers have shown high stability in buffer 11 solution in vitro, they still easily aggregate in the in vivo situation, which is likely a 12 consequence of proteins and cells in the biological fluids interacting with nanocarriers. 13
This aggregation in turn further leads to rapid clearance of nanocarriers and poor 14 therapeutic efficacy [6] [7] [8] . Modification of the particles with poly(ethylene glycol) (PEG) 15 on the surface is a frequently applied method to decrease protein interaction and 16 increase their stability in biological fluids [9, 10] . Reduction of protein adsorption in the 17 circulation can also decrease recognition and clearance by the mononuclear phagocyte 18 system (MPS) in liver and spleen [11, 12] . PEG molecular weight and PEG surface density 19 are two major factors that determine in vivo performance. Thicker PEG layers that are 20 formed with longer and denser PEG chains on the surface of particles normally lead to 21 better shielding [11, 13] . The effect of the degree of PEGylation on in vivo performance of 1 nanomedicines is usually evaluated by studying pharmacokinetics and biodistribution 2 in animals. Although it may be a straightforward approach, animal studies entail ethical 3 issues and are time and cost consuming. There is thus an urgent need for better and 4 more predictive in vitro characterization techniques that enable formulation 5 optimization before in vivo experiments. 6
Injected nanocarriers may result in potential toxicity and hazard healthy tissues in 7 the body and biocompatibility and biodegradability are therefore crucial for 8 nanocarriers [14] . Besides, the degradation behavior of drug-loaded nanocarriers can also 9 alter the release and consequently the biodistribution of payloads [15] . Therefore, 10 optimization of the degradation behavior of drug delivery system should be investigated 11 to fulfill different requirements for various biomedical purposes. Several in vitro 12 characterization techniques have been investigated to evaluate the degradation behavior 13 of nanocarriers. A common method is to measure their weight loss during incubation [16, 14 17] . Determination of changes in particle size as well as particle concentration in the 15 suspension has also been investigated [18, 19] . Assaying the degradation products is 16 another way to study the degradation kinetics of nanoparticles [19] [20] [21] . However, while 17 these techniques can provide important information about the physicochemical 18 characteristics of the material used, they have limited predictive value for their in vivo 19 performance as nanocarrier drug formulations. 20
This article reports on three techniques that were specifically adopted and 1 optimized to more accurately investigate and predict in vivo performance of nanocarrier 2 formulations. Nanogels are nanosized hydrogel particles consisting of water-swollen 3 hydrophilic polymeric networks. They possess combined attractive features of hydrogel 4 materials and nanoparticles, such as good biocompatibility, tailorable biodegradability, 5 easy chemical modification, high responsiveness, high colloidal stability and the 6 possibility of targeted delivery of loaded therapeutics after intravenous 7 administration [22] . Therefore nanogels have distinct advantages over other types of 8 nanomaterials for biomedical applications [23] . Moreover, by varying the chemical 9 composition of nanogels, their characteristics such as size, charge, porosity, 10 amphiphilicity, softness, and degradability can be fine-tuned and tailored. Our previous 11 study has shown that pHEMAm-Gly-HEMAm nanogels are cytocompatible and their 12 degradation can be tailored depending on the crosslink density of nanogels [19] . 13 Therefore, PEGylated biodegradable p(HEMAm-co-AzEMAm)-Gly-HEMAm-based 14 nanogels that require in vitro optimization of their degree of PEGylation and crosslink 15 density (Figure 1 and 2) were used as an example. To study the effect of PEG density 16 on particle size, dynamic light scattering (DLS) was used ( Figure 3A) . The 17 stability/aggregation of nanogels upon incubation in human plasma was further studied 18 by fluorescence single particle tracking (fSPT) (Figure 3B ). Tangential flow filtration 19 (TFF) was used as an artificial circulating system to mimic the degradation of 20 PEGylated nanogels with different crosslink densities and filtration of the soluble 21 degradation products from the system in vitro (Figure 3C) . The degradation behavior 1 of PEGylated nanogels with optimized PEG and crosslink densities in PBS and 2 undiluted human plasma were compared using fluorescence fluctuation spectroscopy 3 (FFS) (Figure 3D) . (HEMAm-Gly, degree of polymerization 1.83) and N-(2-azidoethyl)methacrylamide 9 (AzEMAm) were synthesized as previously described [19, [24] [25] [26] . BCN-PEG5000-OMe was 10 purchased from SynAffix BV (Oss, the Netherlands 
Synthesis of copolymer p(HEMAm-co-AzEMAm) 1
The synthesis of azide functionalized copolymers, p(HEMAm-co-AzEMAm) (5-2 20 mol% of AzEMAm), was performed by free radical polymerization using HEMAm 3 and AzEMAm as monomers and ABCPA as the initiator (molar ratio of 4 monomer/initiator was 15:1) according to a previously published procedure. Briefly, 5 the monomers and initiator were dissolved in deionized water at a total concentration 6 of 25 mg mL -1 . After flushing with N2 for 30 min at room temperature, the solution was 7 heated to 70 °C and stirred for 24 h. The products were purified by dialysis (membrane 8 cut-off 3500 Da) against deionized water and recovered after freeze drying. 9 Solid state spectra of the polymer were acquired by accumulating 32 scans per spectrum 8 at a data point resolution of 2 cm -1 . 9
The copolymer composition of the synthesized polymers was quantified by 10 dissolving samples in deuterium oxide and analyzed by 1 H-NMR. The spectra were 11 recorded with an Agilent 400-NMR spectrometer (Santa Clara, CA, USA). The central 12 line of deuterium oxide at 4.75 ppm was used as reference line. The integral intensities 13 I3.46 and I3.65 of protons at 3.46 ppm (AzEMAm) and 3.65 ppm (HEMAm) were 14 recorded and the mol% of AzEMAm in polymers was calculated according to Equation 15
(2). were determined by Viscotek TDAmax (equipped with RI, light scattering and viscosity 21 detectors, Malvern Instruments Ltd., UK) with two PL aquagel-OH 30 columns 1 (Agilent, USA). A 0.3 M sodium acetate buffer (pH 6.5) was used as the eluent with a 2 flow rate of 0.7 mL min -1 . Samples were dissolved in the mobile phase at the 3 concentration of 2 mg mL -1 and injected onto the column (injection volume 100 μL). 4
Results were analyzed by OmniSEC software (Malvern Instruments Ltd., UK) with 5 poly(ethylene oxide) (Mn: 19 kDa, PDI: 1.04, Malvern Instruments Ltd., UK) as the 6 calibration standard. 7 8
Labeling of copolymer 9
A labeled copolymer was obtained by copper-free click chemistry reaction 10 between the azide groups of copolymer and DIBO groups of Alexa 488 DIBO. Briefly, 11 10 mg copolymer (containing 20 mol% AzEMAm) was dissolved in 1 mL of 12 ammonium acetate buffer (100 mM, pH 5) and 10 μL of Alexa 488 DIBO (1 mg mL -1 13 in DMSO) was added. The mixture was stirred at room temperature for 1 h. The labeled 14 copolymer was purified by PD 10 chromatography and recovered after freeze drying. 15 16 were prepared as previously described [19, 24] . Briefly, CDI activated HEMAm-Gly 20 (HEMAm-Gly-CI) was obtained by reaction of the hydroxyl group of HEMAm-Gly 1 (degree of polymerization 1.83) with CDI. Subsequently, HEMAm-Gly-CI was coupled 2 to p(HEMAm-co-AzEMAm) in the presence of DMAP. 3 4
Synthesis of p(HEMAm-co-AzEMAm)-Gly-HEMAm

Preparation, PEGylation and labeling of empty nanogels 5
The preparation of empty nanogels was carried out according to previous studies [19, 6 27] . In brief, p(HEMAm-co-AzEMAm)-Gly-HEMAm (37.5 mg) dissolved in DMSO 7 (212.5 μL) was mixed with Irgacure 2959 (150 μL, 10 mg mL -1 in distilled water). The 8 mixture was added to 5 mL of mineral oil (containing 10% v/v ABIL EM 90) and 9 subsequently vortexed. The formed emulsion was further sonicated by a tip sonicator 10 (Bandelin Sonopuls, pulse on/off 0.5 s, and amplitude 10%) for 15 min and irradiated 11 under UV (940 mW cm -2 , 300-650 nm, Bluepoint UVC source, Honle UV technology, 12
German) for 15 min. Next, the emulsion was mixed with 40 mL acetone and centrifuged. 13
The pellet was further washed with 40 mL acetone/hexane (1:1, v/v) for four times. 14 After the organic solvent was removed under vacuum, the pellet was redispersed in 15 water and lyophilized. 16
To modify nanogels with PEG, 10 mg freeze dried nanogels was dispersed in 1 17 mL of ammonium acetate buffer (100 mM, pH 5) and PEG5000-BCN solution (10 mg 18 mL -1 in pH 5 ammonium acetate buffer) was added. The volume of PEG5000-BCN 19 solution was 0.25, 0.5 and 1 mL for nanogels prepared from copolymers with 5, 10 or 20 20 mol% of AzEMAm respectively to make sure the molar ratio of PEG to azide groups 1 (1:10) was the same for the different copolymers. The mixture was stirred at room 2 temperature for 4 h, followed by ultracentrifugation (250,000×g for 1 h) to remove 3 unreacted PEG-BCN. 4
The PEGylation efficiency was determined by measuring the amount of unreacted 5 PEG5000-BCN in the supernatant after ultracentrifugation. The determination was 6 performed by Viscotek TDAmax with a PL aquagel-OH 30 column, using ammonium 7 acetate buffer (100 mM, pH 5) as the eluent. The flow rate was 0.7 mL min -1 and the 8 injection volume was 100 μL and the light scattering signal was recorded. The 9 calibration curve of PEG5000-BCN was linear between 1 and 10 mg mL -1 . The 10
PEGylation efficiency was calculated according to Equation (3). Labeling of PEGylated and non-PEGylated nanogels with Alexa 488 was 15 performed according to a previously reported procedure [26] . Freeze dried nanogels (10 16 mg) were dispersed in 1 mL of ammonium buffer (100 mM, pH 5) and 10 μL of Alexa 17 488 DIBO (1 mg mL -1 in DMSO) was added. The mixture was stirred at room 18 temperature for 1 h. The labeled nanogels were purified by PD 10 chromatography and 19 recovered after freeze drying. 20
The size and size distribution of re-suspended nanogels (0.5 mg mL -1 in 20 mM 1 HEPES pH 7.4) were measured by dynamic light scattering (DLS, Malvern ALV/CGS-2 3 Goniometer, Malvern, UK) at 25 °C. The zeta potential of nanogels in 20 mM HEPES 3 (pH 7.4) was measured using a Malvern Zetasizer Nano-Z (Malvern, UK) at 25 °C. 4 5 2.7 Stability of nanogels using fluorescence single particle tracking (fSPT) 6
fSPT assay was carried out to study the stability/aggregation of DS 20 nanogels 7 with different PEGylation degrees in full human plasma. A custom-built laser widefield 8 epi-fluorescence microscope was set-up as described by Breackmans et al [28] . Labeled 9 nanogels (concentration of 10 9 to 10 12 particles per mL) were incubated in human 10 plasma for 1, 2, 3 and 4 h at 37 °C. At each time point, 5 μL of sample was taken and 11 introduced in a microscope slide and cover glass with double-sided adhesive tape. The 12 samples were excited using widefield laser illumination. Movies of individual nanogels 13 diffusing in the medium (10 to 20 movies of 8 seconds per sample) were recorded and 14 analyzed using custom-developed software. By calculating the diffusion coefficient for 15 each trajectory, the size distribution of nanogels in the medium was obtained after 16 transformation of obtained distribution of empirical diffusion coefficients using the 17
Stokes-Einstein equation [28] . The viscosity of human plasma was set to 1.35 cP at 37 °C 18 for the calculations. The size distribution of nanogels in phosphate buffered saline (PBS, 19 pH 7.4, containing 0.049 M NaH2PO4, 0.099 M Na2HPO4, and 0.006 M NaCl) was 20 measured as a control. 0.5% (wt%) Tween 20 and the processing volume was 15 mL. The retentate was 9 directed back to the sample reservoir and fresh eluent was fed into the sample reservoir 10 from the buffer reservoir at the same rate as filtrate was being generated to maintain the 11 constant volume in the system. The experiment was done at 37 °C with flow rate 15 mL 12 min -1 and operating pressure 10-20 psi. Before the experiment, the whole system was 13 washed with 0.05 M NaOH and rinsed with deionized water thoroughly. Afterwards, At designated time points, the volume of retentate was recorded and 0.5 mL retentate 20 samples were taken. The samples were further incubated in an oven at 37 °C with a 1 total of 144 h incubation time (during TFF and in the oven) to degrade the remaining 2 particles [19] and analyzed using Jasco FP8300 spectrofluorometer (JASCO Benelux 3 B.V., IJsselstein, the Netherlands). The fluorescence intensity (λex. = 495 nm, λem. = 519 4 nm) was recorded and the concentration was calculated according to the calibration 5 curve of Alexa 488 DIBO (linear at aconcentration ranging from 0.01 to 1 μg mL -1 ). 6
The normalized amount of materials in the retentate was calculated using Equation (4). was incubated in sodium borate buffer (100 mM, pH 9) at the same concentration in 20 PBS or plasma at 37 °C for 6 h. The procedure was similar as previously described by 1
Buyens et al. [29] and Novo et al. [30] , with some modifications. Briefly, FFS 2 measurements were performed on Alexa 488 labeled PEGylated nanogels (20%, (Figure 1) were 5 synthesized to investigate the stability and degradation of nanogels based on these 6 polymers with different degrees of PEGylation and crosslink densities. 7
The polymers were synthesized in two steps. First, p(HEMAm-co-AzEMAm) with 8 different AzEMAm mol% (5-20%) was synthesized by free radical polymerization 9 using HEMAm and AzEMAm as monomers and ABCPA as initiator (Figure S1A) [26] . 10
The 1 H-NMR spectra of p(HEMAm-co-AzEMAm) displayed a resonance peak of 11 AzEMAm group at 3.46 ppm (Figure S1B) . The characteristics of the obtained 12 copolymers are summarized in Table 1 . All copolymers were obtained with good yields 13 (> 80%) as reported previously [26] . The number average molecular weight ranged from 14 10 to 15 kDa, which is smaller than kidney elimination threshold (45 kDa) [31] , with a 15 PDI around 3. Complete conversions of HEMAm (98%) and AzEMAm (99%) were 16 obtained after polymerization and the ratio of HEMAm to AzEMAm in the copolymer 17 was the same as the feed ratio for all copolymers. IR analysis further showed a 18 characteristic peak at 2100 cm -1 of the azide vibration, the intensity of which increased 19 with increasing AzEMAm content (Figure S1C) . 20
The copolymers were further modified with crosslinkable methacrylamide side 21 unit which contains hydrolytically biodegradable ester bonds (Figure S1A) [32] . 1
Copolymers with three different DSs (5, 10 and 20) were synthesized for each 2 p(HEMAm-co-AzEMAm) and thus nine different p(HEMAm-co-AzEMAm)-Gly-3 HEMAm were obtained. 4 5
Preparation, PEGylation and labeling of nanogels 6
Nanogels with different crosslink densities and contents of AzMEAm were 7 obtained with a yield around 80%. Afterwards, PEG5000-BCN was conjugated to the 8 surface of nanogels by copper-free click chemistry reaction (i.e. strain-promoted azide-9 alkyne cycloaddition (SPAAC)) of azide and BCN groups under mild reaction 10 conditions [33] . This reaction not only has the benefits of normal click chemistry such as 11 high reactivity and selectivity [34] , but also avoids the use toxic metal catalyst. [35] The 12
properties of nanogels are summarized in Table 2 . Before PEGylation, the size of 13 nanogels ranged from 160 to 230 nm with PDI of about 0.2 and the particles were 14 neutral at pH 7.4. After PEGylation, the zeta potential did not change whereas the size 15 of the nanogels slightly increased (e.g. from about 203 to 208 nm for DS 5 and 5% 16 nanogels) after PEGylation due to the thickness of the PEG layer. Besides, the 17 difference in size before and after PEGylation increased with an increasing PEG content. 18 E.g looking at the DS 5 nanogels (Table 2) one can find that PEGylation increases the 19 particle size by 5, 10 and 20 nm for nanogels containing 5%, 10% and 20% AzEMAm%, 20 respectively. Many studies have shown that PEG chains have a "mushroom" 1 conformation when the surface density is low, while the chains are forced in a "brush" 2 conformation at high surface densities leading to an increase of layer thickness from 10 3 to 20 nm (5 kDa PEG) [10, 13, 36] . 4
PEGylated and non-PEGylated nanogels were further labeled with Alexa 488 5 using copper-free click chemistry reaction between the DIBO group of the dye and the 6 remaining azide groups of nanogels, and the labeling efficiency was over 80% (Figure  7 S2). These labeled nanogels were used for further studies. biofluids. [37] This technique records the movement of individual fluorescently labeled 13 nanoparticles, calculates the diffusion coefficient based on the their trajectories and 14 converts this to the size distribution of dispersed nanoparticles [28] . Therefore, fSPT was 15 used to evaluate the influence of PEGylation on the colloidal stability of the nanogels 16 in undiluted human plasma. Alexa 488 labeled nanogels (DS 20) with different degrees 17 of PEGylation were incubated at 37 °C in human plasma. Nanogels with the highest 18 crosslink density (DS 20) and thus highest stability [19, 27] were chosen in this study to 19 minimize the effect of nanogel degradation on particle aggregation during the stability 20 study. The size distribution of nanogels in plasma was determined by fSPT after 1 different incubation times and compared with that of nanogels dispersed PBS buffer 2 (pH 7.4) (Figure 6) . The size distributions of DS20 nanogels in PBS measured by fSPT 3 were comparable to that obtained from DLS data (average size ranged from 250 to 300 4 nm). fSPT analysis showed a change in particle size distribution upon incubation in 5 human plasma at 37 °C over time. Increased colloidal stability was observed with an 6 increasing degree of PEGylation of the nanogels. For non-PEGylated 5% nanogels 7 (Figure 6A) , the average size increased from 250 nm to over 1000 nm after 1 h 8 incubation in plasma. After 2 h incubation, complete aggregation was observed and the 9 sample was not suitable for further quantitative measurements. For nanogels with 5% 10
PEGylation which is the lowest PEGylation degree, the average size of particles 11 increased from 250 to 700 nm after 4 h incubation in plasma at 37 °C (Figure 6B) . The 12 size distribution was much broader than at the start of the experiment. It has been shown 13 that protein adsorption contributes to aggregation of nanocarriers [38, 39] . This result 14 demonstrates that this degree of PEGylation (5%) cannot fully prevent protein 15 absorption. For nanogels with 10% PEG5000, a clear change of size distribution can 16 already be seen after 1 h incubation in plasma (Figure 6C) and an increased average 17 size (460 nm) and large aggregations (> 500 nm) were observed after 2 and 3 h of 18 incubation, respectively. Nanogels with the highest degree of PEGylation (PEGylated 19 20% nanogels) showed only a slight change of the size distribution after 1 h incubation 20 ( Figure 6D) . Furthermore, no significant change of size distribution was found during 21 further incubation until 4 h and no particle aggregates were detected. This result also 1 confirms the hypothesis from DLS data that PEGylated 20% nanogels had the highest 2 colloidal stability and the best anti-aggregation ability. Interactions between particles 3 with high degree of PEGyation and proteins are decreased due to the shielding 4 properties of the PEG layer, which results in the successful stabilization of colloidal 5 particles in biofluids. The nanogels with 20% PEGylation are expected to show less 6 plasma protein binding and therefore a reduced recognition by the mononuclear 7 phagocyte system and longer circulation time [8, 10, 40] . Therefore, nanogels with 20% 8 PEG and with different crosslink densities were further studied. 9 10
Degradation and filtration of nanogels by tangential flow filtration (TFF) 11
Nanogels prepared from building blocks of different degrees of substitution 12 (Figure 1) have different crosslink densities, which in turn lead to different degradation 13 kinetics [19, 41] . When they are i.v. injected, they slowly degrade, finally yielding 14 p(HEMAm-co-AzEMAm) of which the average molecular is 10 kDa, which is lower 15 than the renal elimination threshold (around 45 kDa) and thus can be potentially 16 excreted by the kidneys [31, 42] . As one of main membrane filtration techniques, TFF (or 17 cross flow filtration) has been used for decades to purify and concentrate 18 biotherapeutics in the pharmaceutical industry [43] . Equipped with filters with different 19 molecular weight cut-off (MWCO), TFF also enables purfication [44, 45] , size selection [46] 20 and concentration [47] of nanoparticles. 1
Since membrane separation is the principle of renal filtration for nanocarrier 2 clearance [48] , TFF was used as an artificial circulation and filtration system to predict 3 the circulation times of nanogels with different crosslink densities in vitro (Figure 4A) . 4
The MWCO of the filter was chosen as 50 kDa, which is close to the threshold for renal 5 filtration [31] . The surface area of the filter (20 cm 2 ), process volume (15 mL) and flow 6 rate (15 mL min -1 ) were close to total glomerular capillary surface area, blood volume 7 and flow rate in a healthy rat [49] [50] [51] [52] . During the experiment, the nanogel suspension 8 continuously circulated in the system. Upon incubation, the degradation fragments with 9 molecular weight smaller than molecular weight cut-off (MWCO) of the filter were 10 filtered out from the system by transmembrane pressure (pressure difference between 11 feed and permeate pressure). 12
When a DS 20 nanogel suspension was added to an untreated TFF system, a 13 dramatic decrease of fluorescence intensity of retentate was observed (fluorescence 14 intensity decreased by about 40% in the first 2 h). Given that DS 20 nanogels have slow 15 degradation [19] , the decrease of fluorescence intensity is probably due to unspecific 16 adsorption of nanogels onto tubes and filter membrane. Therefore, the system was first 17 saturated with DS 20 nanogels overnight to block unspecific binding. Alexa 488 labeled 18 p(HEMAm-co-AzEMAm) (20% AzMEAm%, Mn: 10.2 kDa, PDI: 3.5) was used to 19 confirm that after blocking process the filter was still able to filter the degradants (i.e. 20 soluble polymers) based on molecular weight. Figure S3 shows that in time, the amount 21 of polymer in the filtrate increased and its amount in the retentate decreased accordingly. 1
The recovery of fluorescence was over 90% during the experiment, indicating that 2 aspecific binding of the polymer was minimized. After 4 h filtration, almost 80% of the 3 fed polymer was permeated from the circulation and filtered out. Table S1 shows that 4 the molecular weights of the soluble polymers in the filtrate increased slowly and the 5 number average molecular weights were smaller than 50 kDa. The result is in line with 6 the observation of other in vivo studies that around 50% of poly(N-(2-hydroxypropyl) 7 methacrylamide) (pHPMA) (Mn 21.8 kDa, PDI 1.7) was excreted from the kidneys after 8 3 h intravenous administration [31, 53] . After 4 h filtration, more than 20% the polymers 9 retained in the retentate and the number average molecular weight was around 80 kDa 10 with narrow PDI (< 1.2) ( Table S1 ). These results demonstrate that the filter is able to 11 separate polymers based on the differences of molecular weight: small polymers can 12 pass through the membrane and chains with molecular weights higher than MWCO can 13 be intercepted in the retentate. 14 After evaluation of the selectivity of filter membrane, the degradation of nanogels 15 and anticipated clearance of degradants from the pretreated TFF system was studied 16 (Figure 4B) . Since nanogels prepared from polymers with 20% AzEMAm% showed 17 the highest colloidal stability in human plasma after PEGylation by fSPT, nanogels with 18 highest degree of PEGylation (20% AzEMAm%) and various crosslink densities (DS 19 5, 10, 20) were used in this study. The decrease of amount of the retentate was found 20 for all nanogels, indicating that during incubation and circulation, the degradation 21 products could be filtered and removed from the system. Fast filtration was found at the 1 beginning of the experiment (< 10 h incubation).Thereafter, the normalized amounts of 2 materials in the retentate were 60% for DS5, 80% for DS 10 and 85% for DS 20 3 nanogels, respectively. Additionally, a more rapid decrease of the amount of materials 4 was found for nanogels prepared from a lower DS polymer. For example, the 5 normalized amounts of materials in the retentate were about 45% for DS 5, 50% for 10 6 nanogels, and more than 60% for DS 20 nanogels after 72 hours of incubation. This 7 demonstrates that nanogels with lower crosslink density have faster degradation and 8
were consequently more rapidly removed by filtration. Compared to the degradation 9 behavior of nanogels with the same crosslink density which was measured by DLS in 10 the previous study [19] , the decrease of filtration rate obtained by TFF was slower: After 11 48 h incubation, normalized light scattering intensity of nanogel suspension dropped to 12 20% for DS 5 and 10 nanogels, and 40% for DS 20 nanogels as measured by DLS [19] . 13 A possible explanation is that the dissolved fragments from nanogel degradation (which 14 have much weaker light scattering) need to be further hydrolyzed into small fragments 15 and only polymer chains with molecular weight smaller than MWCO can be filtered [54] . 16 Therefore, TFF is able to clearly characterize the degradation behavior of nanogels in 17 terms of crosslink density and can be used as an in vitro tool to predict the in vivo 18 degradation behavior of nanogels. 19 20
Fluorescence fluctuation spectroscopy (FFS) 1
Fluorescence fluctuation spectroscopy (FFS) was chosen to study the degradation 2 behavior of the nanogels in human plasma and PBS. FFS has been previously exploited 3 to study the stability/dissociation of siRNA-polymer complexes in biofluids [29, 30] . In 4 these studies it was shown that the baseline fluorescence intensity of the fluctuation 5 profile is proportional to the free fluorophore-labeled siRNA concentration released 6 from complexes. In the present study this principle was applied to in vitro characterize 7 and predict the in vivo degradation behavior of nanogels. The triazole linkages between 8 the dye and polymer formed by click reaction between azides and alkynes are known 9 to be stable under physiological conditions [55, 56] . Therefore, the detected fluorescence 10 is due to the polymer bound dye and not to the free dye. As shown in fSPT study, 11 nanogels with the highest degree of PEGylation revealed the highest colloidal stability 12 in human plasma. Furthermore, nanogels with medium crosslink density (prepared from 13 DS 10 polymers) showed optimal degradation behavior in vitro by TFF. Therefore, 14
Alexa 488 labeled, PEGylated nanogels prepared from the DS 10 and 20% AzEMAm% 15 polymer were chosen to study the effect of their degradation behavior both in plasma 16 and buffer. At time 0, the low baseline suggests that very little labeled free polymer was 17 present (Figure S4A) . The more intense fluorescence peaks are due to the diffusion of 18 Alexa 488 labeled nanogels in and out of the excitation volume. During the incubation, 19 the nanogels slowly degrade and soluble fragments are released from the nanogels and 20 into medium, which lead to an increased baseline fluorescence (Figure S4B) . Intense 21 fluorescence peaks are still observed at roughly the same frequency, which is probably 1 because nanogels were only partly degraded, so that they still remain fluorescent. The 2 total amount of soluble degradation products was obtained from the baseline 3 fluorescence of fully degraded nanogels incubated under accelerated conditions (pH 9, 4 37 °C, 6 h). Figure S4C shows that under these conditions the nanogels indeed 5 completely degraded since no large fluctuations (pointing to the presence of 6 nanoparticles) in the fluorescence signal were detected. The degree of degradation of 7 nanogels incubated in plasma at 37 °C for 1, 3, 6 and 24 h was calculated by comparing 8 the baseline fluorescence of samples to the total amount of fluorescence (Equation 2). 9
The kinetics of degradation of nanogels in PBS and plasma at 37 °C is presented 10
in Figure 5B . This figure shows that round 30 to 40% of labeled polymer was present 11 in the medium after 3 h incubation in the form of soluble fragments, and the amount of 12 soluble products subsequently increased slowly in time reaching about 60% soluble 13 product after 24 h incubation. Figure 5B also shows that that no significant difference 14 of degradation behavior can be observed in the two media. These results indicate that 15 the degradation of the nanogels is a chemical process in which proteins and enzymes 16 present in plasma have little contribution. 17 18
Conclusions
19
Three techniques were used and optimized to investigate the degradation behavior 20 of nanogels differing in extent of PEGylation and crosslink density. Fluorescence single 21 particle tracking (fSPT) results demonstrate that this is an attractive technique to assess 1 the colloidal stability of the nanogels in biofluids (i.e. human plasma). Tangential flow 2 filtration (TFF) is able to reveal differences in degradation and filtration of nanogels 3 with different degradation behaviors as an artificial in vitro circulation and filtration 4 system. Furthermore, degradation of nanocarriers under biological conditions can be 5 characterized directly in vitro with fluorescence fluctuation spectroscopy (FFS), which 6 is likely predictive for in vivo behavior. All together, these advanced in vitro methods 7 provide extra and valuable information on properties of nanocarriers, and can help 8 identify and optimize nanocarrier-based drug products with desired in vivo behavior 9 prior to animal studies. Fluorescence single particle tracking (fSPT), tangential flow filtration (TFF) and 9 fluorescence fluctuation spectroscopy (FFS) are developed and optimized to study the 10 stability and degradation of polymeric nanogels with various degrees of PEGylation 11 and crosslinking densities. They are valuable in vitro strategies to predict the in vivo 12
behavior of nanocarriers prior to animal studies. AzEMAm%) and DS5 nanogels prepared from polymer with different AzEMA% (n=3). 6 7 8
9 Figure S3 . Normalized amount of polymers in the filtrate and retentate after Alexa 488 10 labeled p(HEMAm-co-AzEMAm) circulated in DS 20 PEGylated nanogels pretreated 11 TFF system at 37 °C for different time. 12 13 14 3 Figure S4 . Fluorescence fluctuation profiles of PEGylated DS 10 nanogels incubated 4 in (A) human plasma for 6 h, (B) human plasma for 24 h, and (C) borate buffer (pH 9) 5
for 6 h. The concentration of nanogels in different media was the same. 6 7
